Monday, February 16, 2026 2/16/2026

Annual HVTN Translational HIV Early Stage Investigator (ESI) Conference

Award Number: R13OD024033
ORGANIZATION: OFFICE OF THE DIRECTOR, NIH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/07/2017
PERIOD OF PERFORMANCE END DATE: 03/31/2028

Group Awards By:

View Award Description

Annual HVTN Translational HIV Early Stage Investigator (ESI) Conference - PROJECT SUMMARY ANNUAL TRANSLATIONAL HIV EARLY STAGE INVESTIGATOR (ESI) CONFERENCE This R13 application requests continued NIH support for four annual conferences for Early Stage Investigators (ESIs) conducting translational HIV vaccine, cure, immunology, and co-infection research with non-human primates (NHPs). These meetings are organized contiguous with the NHP AIDS Symposium and gather ESIs and mentors for scientific networking, career development, and training in translational science skills. In Year 1, the meeting will be held at the Tulane National Primate Center in New Orleans, LA in conjunction with the NHP AIDS Symposium. The conferences are planned by a diverse advisory group of experts in the field including scientists at all stages of their careers. K01 HIV/AIDS Scholars and mentors complete a needs assessment to determine priority topics for the meeting. The advisory committee develops the meeting agenda using the input from this needs assessment. Attendees at the ESI Conferences will participate in training and skill-building activities on important translational scientific topics (e.g., cure, prevention, vaccine, and therapeutic research; NHP models of TB and coinfections); mentoring opportunities with senior and peer investigators (e.g., panel discussions on career development); skill building for research career development training (e.g., ESI funding landscape, how to conduct research with HIV Vaccine Trials Network (HVTN), manuscript writing); “Works in Progress” presentations; and organized networking opportunities with other ESIs and senior investigators (e.g., receptions, speed dating, and small group discussions). The meeting has no registration fee and travel scholarships will be awarded to talented ESIs, with priority for underrepresented applicants, and K01 Scholars and mentors, thus providing opportunities for these groups to continue to interact and support translational science. The inclusion of women, underrepresented minorities and individuals with disabilities will be supported as speakers, attendees, and advisors, with a goal of creating a meeting environment that is welcoming to diverse scientists. HVTN staff will organize the conference and will provide further translational research opportunities by facilitating participation for 3 K01 Scholars at the annual HVTN Full Group Meeting in Washington, DC. These conferences will fill a critical gap in scientific knowledge and workforce development by ensuring that the next generation of diverse ESI are able to facilitate greater translation of research between preclinical NHP studies and clinical trials. Building a workforce for the future composed of scientists with strong translational skills is critical to ending the HIV epidemic and developing HIV vaccines, therapeutics, and cure strategies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $74,999 )
2025	2025	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	001	9	4/10/2025	NON-COMPETING CONTINUATION	$74,999
2025	2023	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	000	7	2/19/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $74,999

Issue Date FY: 2024 ( Subtotal = $74,999 )
2024	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	000	8	3/29/2024	COMPETING CONTINUATION	$60,000
2024	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	001	8	5/9/2024	COMPETING CONTINUATION	$14,999
														Subtotal = $74,999

Issue Date FY: 2023 ( Subtotal = $74,999 )
2023	2023	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	002	7	3/18/2023	NON-COMPETING CONTINUATION	$74,999
2023	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	001	6	11/28/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$54,601
2023	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	000	5	11/28/2022	NON-COMPETING CONTINUATION	-$54,601
														Subtotal = $74,999

Issue Date FY: 2022 ( Subtotal = $74,999 )
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	001	6	6/9/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$74,999
2022	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	000	5	6/8/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $74,999

Issue Date FY: 2021 ( Subtotal = $74,999 )
2021	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	002	5	3/20/2021	NON-COMPETING CONTINUATION	$74,999
2021	2020	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	001	4	3/8/2021	COMPETING CONTINUATION	$23,079
2021	2019	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	000	3	3/8/2021	NON-COMPETING CONTINUATION	-$23,079
														Subtotal = $74,999

Issue Date FY: 2020 ( Subtotal = $74,999 )
2020	2020	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	000	4	2/1/2020	COMPETING CONTINUATION	$67,499
2020	2020	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	001	4	4/29/2020	COMPETING CONTINUATION	$7,500
														Subtotal = $74,999

Issue Date FY: 2019 ( Subtotal = $74,999 )
2019	2019	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	000	3	3/5/2019	NON-COMPETING CONTINUATION	$74,999
														Subtotal = $74,999

Issue Date FY: 2018 ( Subtotal = $74,999 )
2018	2018	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	001	2	7/2/2018	NON-COMPETING CONTINUATION	$7,500
2018	2018	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	000	2	4/2/2018	NON-COMPETING CONTINUATION	$67,499
														Subtotal = $74,999

Issue Date FY: 2017 ( Subtotal = $74,999 )
2017	2017	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Research Infrastructure Programs	000	1	4/7/2017	NEW	$74,999
														Subtotal = $74,999

Grand Total All Awards = $674,991

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Annual HVTN Translational HIV Early Stage Investigator (ESI) Conference

Award Number: R13OD024033

ORGANIZATION: OFFICE OF THE DIRECTOR, NIH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/07/2017

PERIOD OF PERFORMANCE END DATE: 03/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer